CLAIM #48472 · Pfizer Inc (PFE) · 2024Q3 earnings call · Oct 29, 2024 · due Dec 31, 2025
“We also are working toward our immunobridging study in 2025 in China, so that we can do an NDA filing, which is also an important market for us.”
Alexandre de Germay · Executive
PENDING
graded after results covering Dec 31, 2025 are reported
Verify independently
SEC filings for PFE ↗ · Claim quote is verbatim from the 2024Q3 earnings call.